Expertise in
8
conditions

Dr. Jessica M. Clement

Hematology | Oncology
Office
85 Seymour St, 
Hartford, CT 
Expertise in
8
conditions
Office
85 Seymour St, 
Hartford, CT 

Overview

Jessica Clement is a Hematologist and an Oncologist practicing medicine in Hartford, Connecticut.

Dr. Clement is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, and Non-Muscle Invasive Bladder Cancer.

She is actively involved in clinical research, co-authoring 20 peer reviewed articles and participating in 4 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in CT

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Office
85 Seymour St, Hartford, CT 06106
Other Locations
Hartford Healthcare Cancer Institute
85 Retreat Ave, Hartford, CT 06106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Biological, Other
Study Drugs: Gemcitabine, Cisplatin, Pegfilgrastim
Study Phase: Phase 2
A Prospectively Designed Study to Assess the Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
A Prospectively Designed Study to Assess the Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
Enrollment Status: Completed
Publish Date: March 19, 2024
Intervention Type: Drug
Study Drug: STP705
Study Phase: Phase 1
View 3 Less Clinical Trials

20 Total Publications

Municipal Pathways in Response to COVID-19: A Strategic Management Perspective on Local Public Administration Resilience.
Municipal Pathways in Response to COVID-19: A Strategic Management Perspective on Local Public Administration Resilience.
Journal: Administration & society
Published: January 06, 2023
Similar Doctors
Expertise in
11
conditions
Dr. Farzana D. Pashankar
Hematology | Oncology
Expertise in
11
conditions
Dr. Farzana D. Pashankar
Hematology | Oncology
Referral may be required

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (33.8 miles away)
203-785-4081
Languages Spoken:
English
See accepted insurances

Farzana Pashankar is a Hematologist and an Oncologist practicing medicine in New Haven, Connecticut. Dr. Pashankar is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Germ Cell Tumor, Teratoma of the Mediastinum, Testicular Yolk Sac Tumor, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
15
conditions
Dr. Michael S. Isakoff
Hematology | Oncology | Pediatrics
Expertise in
15
conditions
Dr. Michael S. Isakoff
Hematology | Oncology | Pediatrics
Referral may be required

CCMC - Hematology

282 Washington St, 
Hartford, CT 
 (0.1 miles away)
860-545-9630
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Isakoff is a Hematologist and an Oncologist practicing medicine in Hartford, Connecticut. Dr. Isakoff is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Osteosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Isakoff is board certified in American Board Of Pediatrics and American Board Of Pediatrics, Pediatric Hematology & Oncology, Pediatric Hematology Oncology . Dr. Isakoff is currently accepting new patients.

Expertise in
27
conditions
Dr. Jeffrey M. Kamradt
Hematology | Oncology
Expertise in
27
conditions
Dr. Jeffrey M. Kamradt
Hematology | Oncology
Referral may be required

Hartford Healthcare Medical Group

85 Retreat Ave, 
Hartford, CT 
 (0.1 miles away)
860-972-4183
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeffrey Kamradt is a Hematologist and an Oncologist practicing medicine in Hartford, Connecticut. Dr. Kamradt is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Chromophobe Renal Cell Carcinoma, and WT1-Related Wilms Tumor Syndromes.

Frequently Asked Questions about Dr. Jessica M. Clement

How do I make an appointment with Dr. Jessica M. Clement?

You can book an appointment with Dr. Jessica M. Clement by calling their office at 860-249-6291. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jessica M. Clement a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jessica M. Clement is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jessica M. Clement specialize in?

While Dr. Jessica M. Clement is a Hematology, they have specific expertise in Prostate Cancer, Familial Prostate Cancer, and Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jessica M. Clement participate in research or clinical trials?

Yes. Dr. Jessica M. Clement has published 20 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Jessica M. Clement's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Clement's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 39 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile